Magazine Article | September 1, 2020

Eyes On Horizon, Buying Into Bio

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Horizon Therapeutics is one fiscally aware company that has put its money to work. Its original model was specialty pharma, which meant acquiring commercial drugs and remarketing them, usually in improved form. Now it is part of a trend of specialty pharma and other commercial companies entering the heart of the biopharma sector.

Revenues from its marketed products are fueling an integrated company with R&D focusing more on bio-based medicines such as monoclonal antibodies and genetically engineered proteins. Tim Walbert, its founding chairman, president, and CEO, has witnessed and directed the company’s transformation.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: